19 May 2021 – Distribution Partnership for the Middle East and Africa

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Distribution Partnership for the Middle East and Africa
Yourgene and Alliance Global launch partnership across multiple territories

Manchester, UK – 19 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it is launching a Distribution Partnership with Dubai-headquartered Alliance Global FZ LLC (‘AGBL’ or ‘Alliance Global’) across a broad range of territories in the Middle East and Africa to expand the Company’s geographical footprint and its customer base.

Alliance Global is the largest biomedical gateway in the Middle East, Africa, and Asia and is both a well-respected and a long-term partner for many international and U.S. diagnostics groups looking to pursue a strategy of expansion in these regions. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the regions’ emerging healthcare market. AGBL is a well-positioned platform agnostic partner for Yourgene, working with key providers of both PCR and sequencing technologies. AGBL will be focusing on Yourgene’s product portfolio of non-invasive prenatal testing (‘NIPT’), the reproductive health range including Cystic Fibrosis and QST*R rapid aneuploidy analysis, DPYD genotyping and the new size selection and enrichment technologies, Yourgene QS250 and LightBench™.

In response to the restriction on travel to key regions as a result of the COVID-19 pandemic, Yourgene has reviewed it’s strategy for bringing products to market in new territories. Following a review of the Company’s channels across its international markets, the commitment and focus with a local network in the Middle East and Africa provided by AGBL, is expected to generate future growth opportunities for the Company. AGBL has strong technical expertise to distribute and support Yourgene’s growing product range and customer base across these regions, offering an expansive geographic reach and more commercial drivers on the ground to meet the needs of this exciting, emerging international market.

Commenting, Lyn Rees, CEO of Yourgene, said: “This partnership with AGBL is a really exciting progression for Yourgene and our product portfolio as we continue to expand into further territories. AGBL will provide a strong and well positioned channel to allow us to deliver and drive growth for our current and future products. This is a key international market for Yourgene and we look forward to working with AGBL and utilising their expertise to secure further market penetration and geographic expansion.”

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122


N+1 Singer (Joint Corporate Broker)
Aubrey Powell / Tom Salvesen / George Tzimas

Tel: +44 (0)20 7496 3000

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Cawthorne 

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

Mob: 07980 541 893 Mob: 07584 391 303   

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene’s geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.